Genistein resists castration-resistant prostate cancer by inhibiting the androgen receptor pathway

作者：Xiaoping Yu, Lujie Zheng, Jiali Yan, Yan Luo, Xiaolong Song, Tianyu Fu, Xiaoli Peng, Jing-Chang Du, Bin Han, Fei Li, Yanfeng Zhu · 发表于：Journal of Asian Natural Products Research · 年份：2025 · DOI：10.1080/10286020.2025.2464695 · 被引用次数：2 · 研究领域：Prostate Cancer Treatment and Research、Estrogen and related hormone effects、Cholesterol and Lipid Metabolism

Prostate cancer is a prevalent malignancy, often diagnosed at advanced stages and associated with poor prognosis. Genistein, a soybean isoflavone, has demonstrated antitumor effects against castration-resistant prostate cancer in vivo. Our results indicate that genistein effectively downregulates the expression of key enzymes involved in the de novo synthesis pathway, namely AKR1C3, SRD5A2, CYP11A1, and 3βHSD, thus blocking androgen synthesis in CRPC cells. Additionally, genistein inhibits the activation and nuclear translocation of the AR. Collectively, these findings support the potential of genistein as a therapeutic agent for CRPC, highlighting its role in both inhibiting androgen synthesis and disrupting AR signaling.